Viewing Study NCT00815594

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:45 AM
Ignite Modification Date: 2026-07-01 @ 8:43 PM
Study NCT ID: NCT00815594
Status: UNKNOWN
Last Update Posted: 2008-12-30
First Post: 2008-12-29
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Bleb Vascularity Change After Subconjunctival Injection Bevacizumab
Sponsor: Capital Medical University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Bleb Vascularity View
None Conjunctival Scarring View
Keywords:

Keywords

Keyword Brief Keyword Text View
None bleb View
None vascular change View
None bevacizumab View
None trabeculectomy View
None Bleb vascularity associated with increased scarring activity View
None Conjunctival scarring finally leads to the obstruction of the fistula … View
None the recombinant human anti-VEGF antibody could inhibit angiogenesis of conjunctiva. View